Maximizing Pharmaceutical Patent Life Cycles
Maximizing Pharmaceutical Patent Life Cycles
6 professionals on LinkedIn recommend this product
Product Overview
The pharmaceutical industry stands at the edge of the patent cliff. The era of biosimilars is in its infancy. A new pharmaceutical patent paradigm has emerged which has radically altered the Rules of the Pharmaceutical Patent End game.
- Presentations from USPTO, FTC and FDA reps.
- An update on biosimilars
- Discussions on regulatory developments
- Critical case analysis of patent planning
6 Professionals recommend Maximizing Pharmaceutical Patent Life Cycles
All professionals that recommend Maximizing Pharmaceutical Patent Life Cycles
Sort by:
Newest
-
Lisa Jakob,Greater New York City Area
I recommend this product
- August 17, 2011
-
Bart Giddings, Partner at Stoel RivesGreater Salt Lake City Area
This is my favorite Hatch-Waxman conference. The speakers and audience members represent a good mix from both the branded and generics sides. I try to attend every year.- August 8, 2011
-
Griem, Jack, Partner at Loeb & Loeb LLPGreater New York City Area
Very valuable, up-to-date advice in all key areas for pharma professionals. Well worth your time.- August 4, 2011
-
Bruce Pokras, Senior Corporate Counsel at Pfizer
Greater New York City Area
I have been attending and speaking at this conference for a number of years. It is always worthwhile. Learning, networking and CLE credits. A great combination!- August 4, 2011
-
Steve Auten, Vice-President, Head of IP, North America at Sandoz
Greater New York City Area
Always a top-notch program! This is a great event at which to blend your CLE requirements with networking opportunities.- August 3, 2011
-
Richard Parr, Assistant Counsel at MerckGreater New York City Area
American Conference Institute’s Maximizing Pharmaceutical Patent Life Cycles conference brings together corporate, outside counsel and government patent professionals with a variety of experiences and perspectives. I speak each year and find it is a great way to share views and learn new approaches to solving common problems.- August 3, 2011
